| |
Control group
|
TXA 250 mg
|
TXA 500 mg
|
p-value
|
|---|
| |
(n = 45)
|
(n = 45)
|
(n = 45)
| |
|---|
|
WOMAC score✝
|
|
3 months
|
36.7 (8.2)**
|
35.8 (7.6)**
|
35.5 (7.2)**
|
0.42
|
|
6 months
|
25.4 (6.0)**
|
23.1 (6.5)**
|
23.5 (6.6)**
| |
|
1 year
|
15.5 (6.6)**
|
15.1 (6.2)**
|
14.5 (7.1)**
| |
|
p-value within group
|
< 0.001**
|
< 0.001**
|
< 0.001**
| |
|
Knee society knee score✝
|
|
3 months
|
121.7 (10.2)**
|
121.1 (10.1)**
|
123.3 (9.1)**
|
0.91
|
|
6 months
|
141.0 (11.5)**
|
141.2 (9.4)**
|
140.0 (8.9)**
| |
|
1 year
|
148.9 (10.1)**
|
151.2 (9.1)**
|
150.9 (9.3)**
| |
|
p-value within group
|
< 0.001**
|
< 0.001**
|
< 0.001**
| |
|
Complications◆ |
|
Re-clamp
|
6 (13%)
|
1 (2%)
|
0 (0%)*b
|
0.01
|
|
Re-dressing
|
3 (7%)
|
0 (0%)*a
|
0 (0%)*b
|
0.05
|
|
VTE
|
4 (9%)
|
1 (2%)
|
2 (4%)
|
0.35
|
|
Congestive heart failure
|
0 (0%)
|
1 (2%)
|
0 (0%)
|
1.00
|
- ✝ = The values were presented as mean (standard deviation), ◆ = The values were presented as number of patients having that condition (percentage of this group), **; p-value between time < 0.001, *; p < 0.05.
- a = comparison between control and TXA-250 group with p < 0.05.
- b = comparison between control and TXA-500 group with p < 0.05.
